The ability of protein kinases to transfer a phosphate group to target proteins plays an important role in many cellular processes. Scientists at the Max Planck Institute for Medical Research have now developed a novel molecular tool that can monitor these kinase activities both spatially and temporally. This makes it possible to investigate the link between kinase activities and cellular phenotypes in heterogenous cell populations and in vivo.

Cancer can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Center have now developed a method that allows for the first time to reconstruct the temporal development—the evolution—of cancerous cells from a single tissue sample.

An international team of researchers led by Konstanz biologists has identified a molecular mechanism that regulates the activity of N-myristoyltransferases. This enzyme plays a role in biological signalling pathways, where dysregulation can lead to serious illness.

Investing in a healthier future: The HORNBACH Group is supporting the new National Cancer Prevention Center in Heidelberg with a donation of five million euros. In the future, a new laboratory will conduct research into more effective early detection and screening methods.

Scientists have been working on the artificial production of blood for several decades. Making a new discovery, researchers from the Institute for Cellular Biology and Immunology Thurgau at the University of Konstanz, in collaboration with Queen Mary University of London, have come an important step closer to this goal.

The skeletal muscles of men and women process glucose and fats in different ways. A study provides the first comprehensive molecular analysis of these differences. The results possibly give an explanation why metabolic diseases such as diabetes manifest differently in women and men – and why they respond differently to physical activity.

The European Commission has launched a new strategy to make Europe the most attractive place in the world for life sciences by 2030. Life sciences – the study of living systems, from cells to ecosystems – are central to our health, environment and economy. They drive innovation in medicine, food and sustainable production, adding nearly €1.5 trillion in value to the EU economy and supporting 29 million jobs across the Union.

Felix Glang, of the Max Planck Institute for Biological Cybernetics in Tübingen, has been awarded the Otto Hahn Medal in recognition of his achievements in developing new magnetic resonance imaging (MRI) methods. Glang's methods enable clearer and faster brain scans.

For his outstanding achievements in his doctorate at the interface between chemistry and biology, Jonas Wilhelm is awarded an Otto Hahn Medal 2025 by the Max Planck Society. He wrote his thesis in the department Chemical Biology of Kai Johnsson at the Max Planck Institute for Medical Research. In his doctorate, Jonas Wilhelm developed a molecular tool, a biosensor that records and permanently stores biological activities at the cellular level.

Computer scientist Annika Reinke from the German Cancer Research Center (DKFZ) has been awarded the Hector Foundation Prize 2025, endowed with €10,000, for her outstanding work in the field of AI-supported medical image analysis. She received the award for the project Metrics Reloaded, which can significantly improve the quality and reliability of AI-supported image analysis.

Sarcomas in soft tissue usually occur in young people and are difficult to treat. Due to a lack of laboratory models, the causes of their development are poorly understood. A team of researchers has now succeeded in creating mouse models with a functioning immune system that replicate sarcoma types that remain unstudied. The method opens up new avenues for the targeted development of immunotherapies for children and adolescents with sarcomas.

Acquisition will strengthen the mRNA-based cancer immunotherapy candidates, marking BioNTech’s milestone in its oncology strategy. Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. All-stock acquisition has potential to create value for both companies’ shareholders given their complementary capabilities, focus on mRNA, and shared vision.